Published in BJU Int on August 05, 2008
Prostate cancer: diagnosis and staging. Asian J Androl (2008) 1.21
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol (2012) 1.02
Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol (2009) 0.95
Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am (2014) 0.93
Focal therapy: a new paradigm for the treatment of prostate cancer. Rev Urol (2009) 0.91
Robotic ultrasound and needle guidance for prostate cancer management: review of the contemporary literature. Curr Opin Urol (2014) 0.88
Limitations of a contemporary prostate biopsy: the blind march forward. Urol Oncol (2010) 0.86
Prostate focused ultrasound focal therapy--imaging for the future. Nat Rev Clin Oncol (2012) 0.83
Pathology: the lottery of conventional prostate biopsy. Nat Rev Urol (2009) 0.82
Robotic prostate biopsy and its relevance to focal therapy of prostate cancer. Nat Rev Urol (2011) 0.77
Considerations for patient selection for focal therapy. Ther Adv Urol (2013) 0.75
Prostate cancer: improvements in risk stratification of prostate cancer. Nat Rev Urol (2013) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (2006) 5.65
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol (2014) 2.78
The increasing incidence of newborn circumcision: data from the nationwide inpatient sample. J Urol (2005) 2.76
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2013) 2.74
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol (2009) 2.67
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol (2004) 2.39
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Nocturia and quality of life: results from the Boston area community health survey. Eur Urol (2011) 2.34
Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 2.33
The state of prostate MRI in 2013. Oncology (Williston Park) (2013) 2.33
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol (2010) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma. J Urol (2002) 2.23
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis (2009) 2.17
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate (2008) 2.16
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05
Readmissions after major urologic cancer surgery. Can J Urol (2014) 2.05
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol (2009) 2.03
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy. J Urol (2012) 2.01
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer (2005) 1.93
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int (2013) 1.89
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate (2007) 1.74
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Patient education materials about the treatment of early-stage prostate cancer: a critical review. Ann Intern Med (2004) 1.71
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int (2007) 1.71
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer (2008) 1.71
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64